The market for Penicillins and Streptomycins in France, expressed in dosage value per capita, showed a decrease from 2013 to 2015, stabilizing around 9.5 to 10.7 USD in subsequent years. By 2023, the value stood at 11.21 USD per capita. Year-on-year, 2023 saw a slight decrease compared to 2022. Over the past two years, the variation demonstrates a modest decline. The Compound Annual Growth Rate (CAGR) over the last five years reflects a minor increase, strengthening the market post-2020.
Future trends to watch include potential shifts due to healthcare policy changes and the global push towards antibiotic stewardship. Economic factors and emerging resistance patterns could also influence market dynamics.
